KKR acquires Medicover India in $1.5 billion hospital expansion

KKR is acquiring Medicover India for about $1.5 billion, its third hospital purchase in three years, building a southern India platform on rising tertiary-care demand and insurance penetration.

"We are pleased to invest in Medicover India and look forward to contributing to its next phase by investing behind its talent, technology, infrastructure and clinical capabilities," said Akshay Tanna, partner and head of India private equity at KKR.

The transaction includes a 100 percent stake sale by existing shareholders plus a commitment to deploy fresh capital. KKR will spend Rs 13,000-14,000 crore in total, roughly a quarter of which — Rs 3,000-4,000 crore — will go into the company as primary capital. Medicover India operates 24 hospitals with approximately 4,800 beds across South and West India, providing care across more than 80 clinical specialties supported by more than 1,900 doctors. The chain's holding company, Sahrudaya HealthCare Pvt Ltd, posted revenue of $217.25 million in FY25, up 13 percent, with EBITDA of $25.68 million at an 11.82 percent margin, though it reported a net loss of $23.69 million.

The deal extends KKR's aggressive push into Indian hospitals after exiting Max Healthcare with a fivefold return. SHPL projects around Rs 400 crore in EBITDA for FY27, expected to jump to Rs 600 crore within a year as recent capacity expansions begin generating revenue. India contributes 10-11 percent of Medicover AB's global revenue but drives a substantial share of patient volumes.

Building a Southern Platform

KKR has been systematically acquiring regional hospital chains. In 2025, it took a controlling stake in Healthcare Global Enterprises, an oncology-focused chain, from founder BS Ajaikumar and shareholders including CVC Capital Partners. It also competed for Manipal Hospitals, India's second-largest hospital chain, before losing to Singapore's Temasek in 2023. Its credit arm extended $600 million in financing to Manipal Education and Medical Group last year.

Medicover India's network spans women's and children's hospitals and cancer institutes. Cardiology and neurology accounted for 34 percent of inpatient revenue in FY25, and the chain plans to expand oncology and other specialties, according to an ICRA report. The company carries Rs 2,264.5 crore of debt as of September 30, 2025, mostly external commercial borrowings from the parent.

Financial Trajectory and Sector Momentum

SHPL's continued net losses stem from the incipient stage of newer hospitals during sizeable capacity expansions over the past four years, which eroded net worth and resulted in modest debt protection metrics, the ICRA report said. Medicover invested about Rs 2,000 crore in India over the last seven years, including a new 300-bed hospital in Secunderabad and Navi Mumbai's first advanced trauma centre.

India has been one of the fastest-growing markets for the Swedish chain, with high-teens revenue growth outpacing the group's 16.7 percent organic rate in 2024. Medicover AB, listed on Nasdaq Stockholm, entered India in 2017 — the same year it went public — by acquiring a controlling stake in Hyderabad-based Sahrudaya Healthcare, the operator of the MaxCure hospital chain. Abc Medicover Holdings BV holds about 66.9 percent of the Indian operations, with the rest owned by founding doctors led by chairman and managing director Anil Krishna Gundana.

The hospital segment remains the primary growth engine of India's healthcare sector, with revenue and EBITDA growth across major operators above 15 percent year-on-year, according to an EY-Parthenon report. Occupancy levels typically range between 60 and 75 percent, with high-acuity specialties such as cardiology and oncology growing at rates exceeding 15 percent in certain cases. The sector's momentum reflects India's National Health Policy 2017 objectives of expanding healthcare infrastructure and access, which has drawn sustained private capital into hospital chains.

KKR has invested more than $20 billion across the global healthcare ecosystem since 2004. The Medicover India deal is subject to regulatory approvals, with Kotak Mahindra and Rothschild advising on the transaction. A formal announcement is expected this week. The acquisition follows a wave of private equity activity in Indian hospitals, as investors bet on rising healthcare spending, expanding insurance coverage and the shift toward higher-acuity treatments.

This article is for informational purposes only and does not constitute investment advice.